To recover your password please fill in your email address
Please fill in below form to create an account with us
A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
See ANZCTR for full trial details >
|
Trial Summary: |
To establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal NECs. To explore translational biologic, molecular and functional imaging endpoints to inform future research and improve outcomes for NEC patients. |
|
Supported By: |
Specialised Therapeutics Australia (STA), AGITG and the NHMRC. |
|
Eligibility: |
Adults with histologically confirmed advanced and/or metastatic, WHO ENET Grade 3, unresectable gastrointestinal NECs, including both small cell and large cell-NEC. |
|
Registration ID: |
ACTRN12616000958482 |
|
Participation: |
Australia |
|
Australian Lead Group: |
AGITG |
|
Status: |
Closed |
|
Activation Date: |
15/09/2016 |
|
Chairs: |
Dr Lorraine Chantrill |
|
Contact: |